Meeting
2014 ASCO Annual Meeting
Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).
Authors
Shyam Kumar Tanguturi
Harvard Radiation Oncology Program, Boston, MA
Shyam Kumar Tanguturi , David A. Reardon , Eudocia Quant Lee , Lakshmi Nayak , Laura W Christianson , Margaret C Horvath , Ian F. Dunn , Alexandra J Golby , Mark D Johnson , Elizabeth B Claus , E. Antonio Chiocca , Keith L. Ligon , Brian Michael Alexander , Nils D. Arvold , Patrick Y. Wen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2065)
DOI
10.1200/jco.2014.32.15_suppl.2065
Abstract #
2065
Poster Bd #
30
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma.
First Author: Mitsuaki Shirahata
Poster
2017 ASCO Annual Meeting
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial.
First Author: Hans-Georg Wirsching
Poster
2012 ASCO Annual Meeting
Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE).
First Author: Ghazaleh Tabatabai
Poster
2011 ASCO Annual Meeting
Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
First Author: A. M. P. Omuro